Oxygent perflubron: Phase III

ALLP said further analysis of its 492-patient Phase III trial showed that Oxygent significantly reduced the number of units of

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE